Correct. Leronlimab at twice the dose should absolutely not perform worse than 350mg, which we can now state unequivocally hit its primary endpoint. At a bare minimum it should perform equally with no additional side effect issues. Though it would expect it to outperform the 350mg arm of the trial based on what we’ve seen from our other trials as well as some NASH trials I’ve looked at where the effect ramped up over time. Interim analysis of one drug that escapes my memory had a lower responder rate than the full trial where folks were on the drug longer. You can sometimes mimic that longer effect by increasing the dose, assuming your drug isn’t fully maxed out at the lower dose. LL is not maxed out at 350mg. I think we’ll be looking strong with 700.

As for the share price today, I anticipate it will accelerate as the news spreads, and this news should actually spread better than older stuff. Volume has been low through the first 20 minutes and you can tell there’s fuckery about when a trial is successful and people are selling eleven minutes later. Or, to be fair, maybe some people had orders in to sell at a few cents above the open and they’re just getting triggered. But my vote is on fuckery.